anti-CD19 UCAR-T cells

Phase 1Cell therapy

CChongqing Precision Biotech Co., Ltd

anti-CD19 UCAR-T cells is one of 8 biologic programs targeting Juvenile Dermatomyositis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Juvenile DermatomyositisActive, not recruiting

Juvenile DermatomyositisPhase 1

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Juvenile Dermatomyositis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Approved

1 2

Olumiant

Eli Lilly

Phase 2

1 3

Rituxan

Roche

Phase 2

1 4

Medrol

Pfizer

Phase 2

1 5

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 6

Pregnancy Test

AAssistance Publique - Hôpitaux de Paris

Phase 2

1 7

Pharmacokinetics Study

AAssistance Publique - Hôpitaux de Paris

Phase 2

1 8

anti-CD19 UCAR-T cells

CChongqing Precision Biotech Co., Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Juvenile Dermatomyositis

NCT06686524

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04264039·30 enrolled

Juvenile Dermatomyositis1 trial

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06686524·18 enrolled

B-cell Malignancies1 trial

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04516551·18 enrolled

CAR T Cell Therapy1 trial

Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04638270·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for anti-CD19 UCAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-CD19 UCAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-CD19 UCAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Precision Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: CChongqing Precision Biotech Co., Ltd

anti-CD19 UCAR-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hematologic Malignancies1 trial

Juvenile Dermatomyositis1 trial

B-cell Malignancies1 trial

CAR T Cell Therapy1 trial

References

Drug Info

Quick Facts

Related News